{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:02Z","timestamp":1792114142612,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jocn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jocn.2015.01.022","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T22:22:49Z","timestamp":1432678969000},"page":"1164-1169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Clinical features and impact of myasthenia gravis disease in Australian patients"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefan","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McEniery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2015.01.022_b0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jocn.2015.01.022_b0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4049\/jimmunol.144.4.1276","article-title":"CD4+ T cell response to the human acetylcholine receptor alpha subunit in myasthenia gravis. A study with synthetic peptides","volume":"144","author":"Protti","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2015.01.022_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2015.01.022_b0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"198","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.jocn.2015.01.022_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of Myasthenia Gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2015.01.022_b0035","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.10035","article-title":"Quality of life in patients with myasthenia gravis","volume":"25","author":"Padua","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0040","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1176\/ajp.150.7.1102","article-title":"Anxiety disorders in a neuromuscular clinic","volume":"150","author":"Paradis","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jocn.2015.01.022_b0045","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","article-title":"Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)","volume":"33","author":"Basta","year":"2012","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jocn.2015.01.022_b0060","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0065","doi-asserted-by":"crossref","unstructured":"Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394\u20139.","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"10.1016\/j.jocn.2015.01.022_b0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jocn.2015.01.022_b0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mus.21919","article-title":"Investigation for RAPSN and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients","volume":"43","author":"Alseth","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1254.054","article-title":"Myasthenia gravis (MG): epidemiological data and prognostic factors","volume":"998","author":"Mantegazza","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1196\/annals.1254.055","article-title":"Myasthenia gravis in individuals over 40","volume":"998","author":"Aarli","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0090","doi-asserted-by":"crossref","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1\u221715:01 in the Norwegian population","volume":"7","author":"Maniaol","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2015.01.022_b0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/08916930500050277","article-title":"Infection, vaccines and other environmental triggers of autoimmunity","volume":"38","author":"Molina","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jocn.2015.01.022_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2012.06774.x","article-title":"The etiology of autoimmune diseases: the case of myasthenia gravis","volume":"1274","author":"Bach","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1179\/016164105X49508","article-title":"Role of immunologic cross-reactivity in neurological diseases","volume":"27","author":"Ercolini","year":"2005","journal-title":"Neurol Res"},{"key":"10.1016\/j.jocn.2015.01.022_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia gravis: paradox versus paradigm in autoimmunity","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2015.01.022_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2015.01.022_b0215","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/S0004-282X2002000400001","article-title":"Myasthenic crisis: report of 24 cases","volume":"60","author":"Werneck","year":"2002","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jocn.2015.01.022_b0220","first-page":"11","article-title":"Drugs which may exacerbate or induce myasthenia gravis: a clinician\u2019s guide","volume":"10","author":"Ahmed","year":"2009","journal-title":"Int J Neurol"},{"key":"10.1016\/j.jocn.2015.01.022_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/gm305","article-title":"Emerging patterns of genetic overlap across autoimmune disorders","volume":"4","author":"Richard-Miceli","year":"2012","journal-title":"Genome Med"},{"key":"10.1016\/j.jocn.2015.01.022_b0135","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S1474-4422(07)70132-1","article-title":"Autoimmune disease in families with multiple sclerosis: a population-based study","volume":"6","author":"Ramagopalan","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2015.01.022_b0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0022-510X(90)90215-9","article-title":"Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus","volume":"97","author":"McCombe","year":"1990","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2015.01.022_b0150","first-page":"847393","article-title":"Myasthenia gravis: a review of available treatment approaches","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jocn.2015.01.022_b0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2015.01.022_b0160","first-page":"CD008111","article-title":"Thymectomy for non-thymomatous myasthenia gravis","volume":"10","author":"Cea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2015.01.022_b0165","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mus.1034","article-title":"Quality of life and well-being of patients with myasthenia gravis","volume":"24","author":"Paul","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jocn.2015.01.022_b0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s100720100066","article-title":"Health-related quality of life in patients with myasthenia gravis and relationship between patient-oriented assessment and conventional measurements","volume":"22","author":"Padua","year":"2001","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.23296","article-title":"Myasthenia gravis: sleep quality, quality of life, and disease severity","volume":"46","author":"Martinez De Lapiscina","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0185","first-page":"1167","article-title":"Quality of life of myasthenia gravis patients","volume":"93","author":"Kulkantrakorn","year":"2010","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jocn.2015.01.022_b0230","doi-asserted-by":"crossref","first-page":"e000313","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.jocn.2015.01.022_b0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(00)00367-1","article-title":"Cognitive dysfunction in individuals with myasthenia gravis","volume":"179","author":"Paul","year":"2000","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2015.01.022_b0200","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mus.21478","article-title":"Determinants of cognitive impairment in elderly myasthenia gravis patients","volume":"40","author":"Marra","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.01.022_b0205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1207\/s15327752jpa7002_14","article-title":"The development, standardization, and initial validation of the Chicago Multiscale Depression Inventory","volume":"70","author":"Nyenhuis","year":"1998","journal-title":"J Pers Assess"},{"key":"10.1016\/j.jocn.2015.01.022_b0210","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00415-011-5913-4","article-title":"Psychosocial aspects in myasthenic patients treated by plasmapheresis","volume":"258","author":"Chen","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2015.01.022_b0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/bmb\/ldr030","article-title":"The epidemiology of thyroid disease","volume":"99","author":"Vanderpump","year":"2011","journal-title":"Brit Med Bull"},{"key":"10.1016\/j.jocn.2015.01.022_b0240","first-page":"1326","article-title":"Prevalence of asthma in adults in Busselton","volume":"305","author":"Peat","year":"1992","journal-title":"Western Australia. Bmj."},{"key":"10.1016\/j.jocn.2015.01.022_b0245","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-4362.1999.00856.x","article-title":"The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia","volume":"38","author":"Plunkett","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jocn.2015.01.022_b0250","unstructured":"AIHW. A picture of rheumatoid arthritis in Australia. Arthritis series 2009."},{"key":"10.1016\/j.jocn.2015.01.022_b0255","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jocn.2015.01.022_b0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev.nutr.24.012003.132440","article-title":"Vitamin B12 deficiency as a worldwide problem","volume":"24","author":"Stabler","year":"2004","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.jocn.2015.01.022_b0265","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jocn.2015.01.022_b0270","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ajg.2012.130","article-title":"The incidence and risk of celiac disease in a healthy US adult population","volume":"107","author":"Riddle","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jocn.2015.01.022_b0275","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemostasis : JTH"},{"key":"10.1016\/j.jocn.2015.01.022_b0280","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroen Hepatol"},{"key":"10.1016\/j.jocn.2015.01.022_b0285","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1445-2197.1995.tb01696.x","article-title":"Crohn\u2019s disease in the Hunter Valley region of Australia","volume":"65","author":"Anseline","year":"1995","journal-title":"Aust NZ J Surg"},{"key":"10.1016\/j.jocn.2015.01.022_b0290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunop"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T22:20:10Z","timestamp":1691706010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586815000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0967586815000922"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2015.01.022","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and impact of myasthenia gravis disease in Australian patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2015.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}